New Data Shows Levemir Weight Benefit Continues After Two Years of Treatment

Data from two studies showed using Levemir results in less weight gain than with other basal insulins in Type 1 and Type 2 diabetes, according to Danish drugmaker Novo Nordisk.

In a two-year study in Type 1 diabetes, patients treated with Levemir (insulin detemir [rDNA origin] injection) gained less weight and had improved glycemic control compared with those on NPH insulin, Novo Nordisk said.

A second study, PREDICTIVE 303, included more than 5,000 patients with Type 2 diabetes who were switched from NPH insulin or insulin glargine to Levemir over a period of 26 weeks. According to the company, these patients lost weight, while experiencing improvements in glycemic control and reduced rates of hypoglycemia. 

The findings on weight gain were consistent with 13 published studies, the company added.